Back to News
Market Impact: 0.38
PureTech Advances LYT-200 In Blood Cancer Program After FDA Feedback, Fast Track Status
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
PureTech Health said the FDA completed its End-of-Phase 1 review for LYT-200 and granted Fast Track designation for treatment of relapsed/refractory high-risk myelodysplastic syndromes. The designation may accelerate development and regulatory engagement for the experimental therapy, representing a positive clinical and regulatory milestone for PureTech.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
PRTC0.80
More News
- Moderna’s Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson’s drug
- PureTech’s LYT-200 receives FDA fast track for blood cancer
- Paramount agrees invest $1.5 billion in domestic movies and create a board for editorial independence at CNN, CBS as part of deal for Warner Bros.
- Paramount and state AGs will settle lawsuit, allowing Warner Bros. merger to proceed, reports say
- Paramount Set to Settle Lawsuits, Clearing Way for Warner Bros. Deal
- Paramount settles with US states in step towards merger with Warner Bros